{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T02:16:00Z","timestamp":1771899360138,"version":"3.50.1"},"reference-count":12,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:00:00Z","timestamp":1607040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Neisseria meningitidis is a gram-negative bacterium that causes a severe acute infection, called the meningococcal disease [...]<\/jats:p>","DOI":"10.3390\/vaccines8040738","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T11:59:00Z","timestamp":1607083140000},"page":"738","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Meningococcal Vaccines: Challenges and Prospects"],"prefix":"10.3390","volume":"8","author":[{"given":"Priyal","family":"Bagwe","sequence":"first","affiliation":[{"name":"Center for Drug Delivery Research, Vaccine Nanotechnology Laboratory, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lotika","family":"Bajaj","sequence":"additional","affiliation":[{"name":"Center for Drug Delivery Research, Vaccine Nanotechnology Laboratory, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2789-5804","authenticated-orcid":false,"given":"Rikhav","family":"Gala","sequence":"additional","affiliation":[{"name":"Fraunhofer USA Center for Molecular Biotechnology, Newark, DE 19711, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7487-8770","authenticated-orcid":false,"given":"Susu M.","family":"Zughaier","sequence":"additional","affiliation":[{"name":"College of Medicine, QU Health, Qatar University, Doha P.O. Box 2713, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad N.","family":"Uddin","sequence":"additional","affiliation":[{"name":"Center for Drug Delivery Research, Vaccine Nanotechnology Laboratory, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin J.","family":"D\u2019Souza","sequence":"additional","affiliation":[{"name":"Center for Drug Delivery Research, Vaccine Nanotechnology Laboratory, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,4]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (WHO) (2020, September 13). Meningococcal Meninigitis: Emergency Preparedness and Response. Available online: http:\/\/www.who.int\/csr\/disease\/meningococcal\/en\/."},{"key":"ref_2","unstructured":"Center for Disease Control and Prevention (CDC), The Pink Book (2020, September 20). Immunology and Vaccines\u2014Preventable Diseases\u2014Meningococcal Disease, Available online: https:\/\/www.cdc.gov\/vaccines\/pubs\/pinkbook\/index.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14760584.2017.1258308","article-title":"The Global Meningococcal Initiative: Global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection","volume":"16","author":"Borrow","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e00566-16","DOI":"10.1128\/CVI.00566-16","article-title":"Recent progress in the prevention of serogroup B meningococcal disease","volume":"24","author":"Feavers","year":"2017","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/21645515.2017.1264750","article-title":"Meningococcal serogroup B vaccines: Estimating breadth of coverage","volume":"13","author":"Donald","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"McCarthy, P.C., Sharyan, A., and Moghaddam, L.S. (2018). Meningococcal vaccines: Current status and emerging strategies. Vaccines, 6.","DOI":"10.20944\/preprints201801.0291.v1"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1128\/IAI.01815-14","article-title":"Recombinant protein truncation strategy for inducing bactericidal antibodies to the macrophage infectivity potentiator protein of Neisseria meningitidis and circumventing potential cross-reactivity with human FK506-binding proteins","volume":"83","author":"Bielecka","year":"2015","journal-title":"Infect. Immun."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/mmi.13747","article-title":"Heterogeneity in non-epitope loop sequence and outer membrane protein complexes alters antibody binding to the major porin protein PorB in serogroup B Neisseria meningitidis","volume":"105","author":"Matthias","year":"2017","journal-title":"Mol. Microbiol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"D\u2019Souza, M.J., Gala, R.P., Ubale, R.V., D\u2019Souza, B., Vo, T.P., Parenky, A.C., Mulla, N.S., D\u2019Sa, S., D\u2019Souza, M., and Braz-Gomes, K. (2015). Trends in Nonparenteral Delivery of Biologics, Vaccines and Cancer Therapies. Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies, Elsevier Inc.","DOI":"10.1016\/B978-0-12-416603-5.00005-5"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Gala, R.P., Ubale, R.V., D\u2019Souza, M.J., and Zughaier, S.M. (2015). Development of Non-Conjugated Meningitis Particulate vaccines. Nanoparticulate Vaccine Delivery Systems, CRC Press.","DOI":"10.1201\/b18096-7"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1016\/j.vaccine.2016.05.010","article-title":"Evaluation of various adjuvant nanoparticulate formulations for meningococcal capsular polysaccharide-based vaccine","volume":"34","author":"Gala","year":"2016","journal-title":"Vaccine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"589","DOI":"10.4155\/cli.12.52","article-title":"Defining efficacy in meningococcal vaccine trials","volume":"2","author":"Keiser","year":"2012","journal-title":"Clin. Investig."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/738\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:41:38Z","timestamp":1760179298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":12,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["vaccines8040738"],"URL":"https:\/\/doi.org\/10.3390\/vaccines8040738","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}